Skip to main content

Table 4 ER visits and hospitalizations post omalizumab therapy

From: Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study

Duration >120 days

Baseline a

Follow-up b

p-valuec

N = 158

N (%)

N (%)

ER visit

  

<0.001*

 Yes

69 (43.7 %)

27 (17.1 %)

 

 No

89 (56.3 %)

131 (82.9 %)

 

Inpatient visit

  

<0.001*

 Yes

55 (34.8 %)

28 (17.7 %)

 

 No

103 (65.2 %)

130 (82.3 %)

 
  1. aBaseline: 1 year before the index date
  2. bFollow-up: 2 months before discontinuation (discontinuation of therapy was defined as a gap in therapy of 56 days)
  3. cFisher’s exact test, *P < 0.05
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us